1
|
Adico MDW, Bayala B, Zoure AA, Lagarde A, Bazie JTV, Traore L, Buñay J, Yonli AT, Djigma F, Bambara HA, Baron S, Simporé J, Lobaccaro JMA. In vitro activities and mechanisms of action of anti-cancer molecules from African medicinal plants: a systematic review. Am J Cancer Res 2024; 14:1376-1401. [PMID: 38590420 PMCID: PMC10998760 DOI: 10.62347/auhb5811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Accepted: 07/27/2023] [Indexed: 04/10/2024] Open
Abstract
Cancer is one of the leading causes of death worldwide. In recent years, African countries have been faced with a rapid increase in morbidity and mortality due to this pathology. Management is often complicated by the high treatment costs, side effects and the increasing occurrence of resistance to treatments. The identification of new active ingredients extracted from endemic medicinal plants is definitively an interesting approach for the implementation of new therapeutic strategies: their extraction is often lower cost; their identification is based on an ethnobotanical history and a tradipratic approach; their use by low-income populations is simpler; this can help in the development of new synthetic molecules that are more active, more effective and with fewer side effects. The objective of this review is to document the molecules derived from African medicinal plants whose in vitro anti-cancer activities and the mechanisms of molecular actions have been identified. From the scientific databases Science Direct, PubMed and Google Scholar, we searched for publications on compounds isolated from African medicinal plants and having activity on cancer cells in culture. The data were analyzed in particular with regard to the cytotoxicity of the compounds and their mode of action. A total of 90 compounds of these African medicinal plants were selected. They come from nine chemical groups: alkaloids, flavonoids, polyphenols, quinones, saponins, steroids, terpenoids, xanthones and organic sulfides. These compounds have been associated with several cellular effects: i) Cytotoxicity, including caspase activation, alteration of mitochondrial membrane potential, and/or induction of reactive oxygen species (ROS); ii) Anti-angiogenesis; iii) Anti-metastatic properties. This review points out that the cited African plants are rich in active ingredients with anticancer properties. It also stresses that screening of these anti-tumor active ingredients should be continued at the continental scale. Altogether, this work provides a rational basis for the selection of phytochemical compounds for use in clinical trials.
Collapse
Affiliation(s)
- Marc DW Adico
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
| | - Bagora Bayala
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
- Ecole Normale SupérieureKoudougou, Burkina Faso
| | - Abdou A Zoure
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
- Laboratoire de recherches Biomédicales (LaReBio), Département de santé publique et biomédicale, Institut de Recherche en Sciences de la Santé (IRSS/CNRST)Ouagadougou, Burkina Faso
| | - Aurélie Lagarde
- Institute Génétique, Reproduction, Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne28, Place Henri Dunant, BP38, F63001, Clermont-Ferrand, France
| | - Jean TV Bazie
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
- Département des Substances Naturelles (DSN), Institut de Recherche en Sciences et Technologies Appliquées (IRSAT)Ouagadougou, Burkina Faso
| | - Lassina Traore
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
| | - Julio Buñay
- Institute Génétique, Reproduction, Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne28, Place Henri Dunant, BP38, F63001, Clermont-Ferrand, France
| | - Albert T Yonli
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
| | - Florencia Djigma
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
| | - Hierrhum A Bambara
- Service d’oncologie, Centre hospitalier universitaire BOGODOGO, Université Joseph KI-ZERBOOuagadougou, Burkina Faso
| | - Silvère Baron
- Institute Génétique, Reproduction, Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne28, Place Henri Dunant, BP38, F63001, Clermont-Ferrand, France
| | - Jacques Simporé
- Laboratoire de Biologie Moléculaire et Génétique (LABIOGENE), Université Joseph KI-ZERBOOuagadougou, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)Ouagadougou, Burkina Faso
- Faculté de médecine, Université Saint Thomas d’Aquin (USTA)Ouagadougou, Burkina Faso
| | - Jean-Marc A Lobaccaro
- Institute Génétique, Reproduction, Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne28, Place Henri Dunant, BP38, F63001, Clermont-Ferrand, France
| |
Collapse
|
2
|
Bayala B, Coulibaly LL, Djigma F, Bunay J, Yonli A, Traore L, Baron S, Figueredo G, Simpore J, Lobaccaro JMA. Chemical Composition of Essential Oil of Cymbopogon schoenanthus (L.) Spreng from Burkina Faso, and Effects against Prostate and Cervical Cancer Cell Lines. Molecules 2023; 28:4561. [PMID: 37299034 PMCID: PMC10254514 DOI: 10.3390/molecules28114561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 05/26/2023] [Accepted: 05/27/2023] [Indexed: 06/12/2023] Open
Abstract
The aim of this research was to evaluate the essential oil of Cymbopogon schoenanthus (L.) Spreng. (C. schoenanthus) from Burkina Faso in terms of cytotoxic activity against LNCaP cells, derived from prostate cancer, and HeLa cells, derived from cervical cancer. Antioxidant activities were evaluated in vitro. Essential oil (EO) was extracted by hydrodistillation and analyzed by GC/FID and GC/MS. Thirty-seven compounds were identified, the major compounds being piperitone (49.9%), δ-2-carene (24.02%), elemol (5.79%) and limonene (4.31%). EO exhibited a poor antioxidant activity, as shown by the inhibition of DPPH radicals (IC50 = 1730 ± 80 µg/mL) and ABTS+. (IC50 = 2890 ± 26.9 µg/mL). Conversely, EO decreased the proliferation of LNCaP and HeLa cells with respective IC50 values of 135.53 ± 5.27 µg/mL and 146.17 ± 11 µg/mL. EO also prevented LNCaP cell migration and led to the arrest of their cell cycle in the G2/M phase. Altogether, this work points out for the first time that EO of C. schoenanthus from Burkina Faso could be an effective natural anticancer agent.
Collapse
Affiliation(s)
- Bagora Bayala
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Département de Biochimie-Microbiologie, Université Joseph KI-ZERBO, Ouagadougou 03 BP 7021, Burkina Faso; (L.L.C.); (F.D.); (L.T.); (J.S.)
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou 01 BP 216, Burkina Faso;
- Institut Génétique, Reproduction & Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne, et Centre de Recherche en Nutrition Humaine Auvergne, 28, Place Henri Dunant, BP38, F63001 Clermont-Ferrand, France
- Ecole Normale Supérieure, Koudougou BP 376, Burkina Faso; (J.B.); (S.B.)
| | - Laetizia Liz Coulibaly
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Département de Biochimie-Microbiologie, Université Joseph KI-ZERBO, Ouagadougou 03 BP 7021, Burkina Faso; (L.L.C.); (F.D.); (L.T.); (J.S.)
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou 01 BP 216, Burkina Faso;
| | - Florencia Djigma
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Département de Biochimie-Microbiologie, Université Joseph KI-ZERBO, Ouagadougou 03 BP 7021, Burkina Faso; (L.L.C.); (F.D.); (L.T.); (J.S.)
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou 01 BP 216, Burkina Faso;
| | - Julio Bunay
- Ecole Normale Supérieure, Koudougou BP 376, Burkina Faso; (J.B.); (S.B.)
| | - Albert Yonli
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou 01 BP 216, Burkina Faso;
| | - Lassina Traore
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Département de Biochimie-Microbiologie, Université Joseph KI-ZERBO, Ouagadougou 03 BP 7021, Burkina Faso; (L.L.C.); (F.D.); (L.T.); (J.S.)
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou 01 BP 216, Burkina Faso;
| | - Silvère Baron
- Ecole Normale Supérieure, Koudougou BP 376, Burkina Faso; (J.B.); (S.B.)
| | - Gilles Figueredo
- LEXVA Analytique, Biopole Clermont-Limagne, F63360 Saint-Beauzire, France;
| | - Jacques Simpore
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Département de Biochimie-Microbiologie, Université Joseph KI-ZERBO, Ouagadougou 03 BP 7021, Burkina Faso; (L.L.C.); (F.D.); (L.T.); (J.S.)
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou 01 BP 216, Burkina Faso;
| | | |
Collapse
|
3
|
Zongo SV, Djigma FW, Yonli AT, Sorgho PA, Nagalo BM, Traore L, Somda D, Amegnona LJ, Languie E, Some CCB, Sia LMJ, Sourabie IB, Sombie RA, Serme AK, Obiri-Yeboah D, Simpore J. Association of DRB1*11 and DRB1*12 alleles of the HLA system with the evolution of the Hepatitis B virus infection in Burkina Faso. Mol Biol Rep 2023; 50:5039-5047. [PMID: 37101005 DOI: 10.1007/s11033-023-08353-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 02/22/2023] [Indexed: 04/28/2023]
Abstract
BACKGROUND Hepatitis B Virus (HBV) infection affect all social strata of humanity and in the absence of any management, this infection has a different outcome from one infected person to another. This suggests that there are specific individual factors that influence the outcome of the pathology. Sex, immunogenetics and age of contraction of the virus have been cited as factors that influence the evolution of the pathology. In this study, we looked at two alleles of the Human Leucocyte Antigen (HLA) system to measure their possible involvement in the evolution of HBV infection. METHOD AND RESULTS We conducted a cohort study involving 144 individuals spread over 04 distinct stages of infection and then compared allelic frequencies in these populations. A multiplex PCR was conducted and the data obtained was analyzed using R and SPSS software. Our study revealed a predominance of HLA-DRB1*12 in our study population without, however, showing a significant difference between HLA-DRB1*11 and HLA-DRB1*12. The HLA-DRB1*12 proportion was significantly higher in chronic hepatitis B (CHB) and resolved hepatitis B (RHB) compared to cirrhosis and hepatocellular carcinoma (HCC) (p-value = 0,002). Carrying HLA-DRB1*12 has been associated with a low risk of complication of infection (CHB → cirrhosis; OR 0,33 p-value 0,017; RHB → HCC OR 0,13; p-value = 0,00,045) whereas the presence of HLA-DRB1*11 in the absence of HLA-DRB1*12 increased the risk of developing severe liver disease. However, a strong interaction of these alleles with the environment could modulate the infection. CONCLUSION Our study shown that HLA-DRB1*12 is the most frequent and it's carriage may be protective in the development of infection.
Collapse
Affiliation(s)
- Sidnooma Véronique Zongo
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso.
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso.
| | - Albert Théophane Yonli
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Pegdwendé Abel Sorgho
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Bolni Marius Nagalo
- Division of Hematology and Oncology, Mayo Clinic, Arizona, 13400 E. Shea Blvd. , Scottsdale, AZ, 85259, USA
| | - Lassina Traore
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Dogfounianalo Somda
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Lanyo Jospin Amegnona
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Eugène Languie
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Couna Christiane Bere Some
- Centre Hospitalier Universitaire Yalgado Ouedraogo (CHU-YO), P.O. Box: 03 BP 7022, Ouagadougou 03, Burkina Faso
| | | | - Issa Boaffi Sourabie
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Roger Arsène Sombie
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Abdel Karim Serme
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, PMB, Cape Coast, Cape Coast, Ghana
| | - Jacques Simpore
- Laboratoire de Biologie Moléculaire Et de Génétique, Université Joseph KI-ZERBO, P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| |
Collapse
|
4
|
Marcellin F, Brégigeon-Ronot S, Ramier C, Protopopescu C, Gilbert C, Di Beo V, Duvivier C, Bureau-Stoltmann M, Rosenthal E, Wittkop L, Salmon-Céron D, Carrieri P, Sogni P, Barré T, Salmon D, Wittkop L, Sogni P, Esterle L, Trimoulet P, Izopet J, Serfaty L, Paradis V, Spire B, Carrieri P, Valantin M, Pialoux G, Chas J, Zaegel-Faucher O, Barange K, Naqvi A, Rosenthal E, Bicart-See A, Bouchaud O, Gervais A, Lascoux-Combe C, Goujard C, Lacombe K, Duvivier C, Neau D, Morlat P, Bani-Sadr F, Meyer L, Boufassa F, Autran B, Roque A, Solas C, Fontaine H, Costagliola D, Piroth L, Simon A, Zucman D, Boué F, Miailhes P, Billaud E, Aumaître H, Rey D, Peytavin G, Petrov-Sanchez V, Levier A, Salmon D, Usubillaga R, Sogni P, Terris B, Tremeaux P, Katlama C, Valantin M, Stitou H, Simon A, Cacoub P, Nafissa S, Benhamou Y, Charlotte F, Fourati S, Poizot-Martin I, Zaegel O, Laroche H, Tamalet C, Pialoux G, Chas J, Callard P, Bendjaballah F, Amiel C, Le Pendeven C, Marchou B, Alric L, Barange K, Metivier S, Selves J, Larroquette F, Rosenthal E, Naqvi A, Rio V, Haudebourg J, Saint-Paul M, De Monte A, Giordanengo V, Partouche C, Bouchaud O, Martin A, Ziol M, Baazia Y, Iwaka-Bande V, Gerber A, Uzan M, Bicart-See A, Garipuy D, Ferro-Collados M, Selves J, Nicot F, Gervais A, Yazdanpanah Y, Adle-Biassette H, Alexandre G, Peytavin G, Lascoux-Combe C, Molina J, Bertheau P, Chaix M, Delaugerre C, Maylin S, Lacombe K, Bottero J, Krause J, Girard P, Wendum D, Cervera P, Adam J, Viala C, Vittecocq D, Goujard C, Quertainmont Y, Teicher E, Pallier C, Lortholary O, Duvivier C, Rouzaud C, Lourenco J, Touam F, Louisin C, Avettand-Fenoel V, Gardiennet E, Mélard A, Neau D, Ochoa A, Blanchard E, Castet-Lafarie S, Cazanave C, Malvy D, Dupon M, Dutronc H, Dauchy F, Lacaze-Buzy L, Desclaux A, Bioulac-Sage P, Trimoulet P, Reigadas S, Morlat P, Lacoste D, Bonnet F, Bernard N, Hessamfar M, Paccalin J, Martell C, Pertusa M, Vandenhende M, Mercié P, Malvy D, Pistone T, Receveur M, Méchain M, Duffau P, Rivoisy C, Faure I, Caldato S, Bioulac-Sage P, Trimoulet P, Reigadas S, Bellecave P, Tumiotto C, Pellegrin J, Viallard J, Lazzaro E, Greib C, Bioulac-Sage P, Trimoulet P, Reigadas S, Zucman D, Majerholc C, Brollo M, Farfour E, Boué F, Polo Devoto J, Kansau I, Chambrin V, Pignon C, Berroukeche L, Fior R, Martinez V, Abgrall S, Favier M, Deback C, Lévy Y, Dominguez S, Lelièvre J, Lascaux A, Melica G, Billaud E, Raffi F, Allavena C, Reliquet V, Boutoille D, Biron C, Lefebvre M, Hall N, Bouchez S, Rodallec A, Le Guen L, Hemon C, Miailhes P, Peyramond D, Chidiac C, Ader F, Biron F, Boibieux A, Cotte L, Ferry T, Perpoint T, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Amiri M, Valour F, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Augustin-Normand C, Scholtes C, Le-Thi T, Piroth L, Chavanet P, Duong Van Huyen M, Buisson M, Waldner-Combernoux A, Mahy S, Salmon Rousseau A, Martins C, Aumaître H, Galim S, Bani-Sadr F, Lambert D, Nguyen Y, Berger J, Hentzien M, Brodard V, Rey D, Partisani M, Batard M, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Fischer P, Gantner et S Fafi-Kremer P, Roustant F, Platterier P, Kmiec I, Traore L, Lepuil S, Parlier S, Sicart-Payssan V, Bedel E, Anriamiandrisoa S, Pomes C, Touam F, Louisin C, Mole M, Bolliot C, Catalan P, Mebarki M, Adda-Lievin A, Thilbaut P, Ousidhoum Y, Makhoukhi F, Braik O, Bayoud R, Gatey C, Pietri M, Le Baut V, Ben Rayana R, Bornarel D, Chesnel C, Beniken D, Pauchard M, Akel S, Caldato S, Lions C, Ivanova A, Ritleg AS, Debreux C, Chalal L, J.Zelie, Hue H, Soria A, Cavellec M, Breau S, Joulie A, Fisher P, Gohier S, Croisier-Bertin D, Ogoudjobi S, Brochier C, Thoirain-Galvan V, Le Cam M, Carrieri P, Chalouni M, Conte V, Dequae-Merchadou L, Desvallées M, Esterle L, Gilbert C, Gillet S, Guillochon Q, Khan C, Knight R, Marcellin F, Michel L, Mora M, Protopopescu C, Roux P, Spire B, Barré T, Ramier C, Sow A, Lions C, Di Beo V, Bureau M, Wittkop L. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH). JHEP Rep 2022; 5:100614. [DOI: 10.1016/j.jhepr.2022.100614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 10/06/2022] [Accepted: 10/07/2022] [Indexed: 11/06/2022] Open
|
5
|
Sagna T, Ouedraogo P, Traore L, Obiri-Yeboah D, Yonli A, Tapsoba A, Tovo F, Sorgho A, Zongo L, Nikiema O, Ilboudo D, Belemgnegre M, Nadembega CW, Ouermi D, Djigma FW, Zohoncon TM, Poaty H, Colizzi V, Simpore J. Enigma of the high prevalence of anti-SARS-CoV-2 antibodies in HIV-positive people with no symptoms of COVID-19 in Burkina Faso. J Public Health Afr 2022; 13:1778. [PMID: 35720802 PMCID: PMC9202456 DOI: 10.4081/jphia.2022.1778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 10/21/2021] [Indexed: 11/23/2022] Open
Abstract
The severe acute respiratory syndrome due to the new coronavirus (SARS-CoV-2), responsible for coronavirus disease (COVID-19), has severely tested the global health response capacity, with predictions of a fatality for developing countries. To evaluate the prevalence of anti-SARS-CoV- 2 antibodies in People Living with HIV (PLHIV) with no COVID-19 symptoms in Burkina Faso. Seroprevalence was estimated by performing a qualitative screening test for SARS-CoV-2-specific immunoglobulins. The STANDARDTM Q COVID-19 IgM/IgG Combo Test kit from SD BIOSENSOR was used. Parameters like HIV plasma viral load, CD4 T cell count and C-Reactive Protein (CRP) expression were estimated. This study enrolled a total of 200 PLHIV aged 4-87 years who are asymptomatic for COVID-19. There were 36 (18%) positive for SARS-CoV-2 IgM and/or IgG of which three (1.50%) were positive for SARS-CoV-2 IgM and 33 (16.50%) for IgG. Among participants diagnosed as IgM positive, 66.67% (2/3) had the highest HIV viral loads with the lowest CD4 T cell counts (p<0.0001). The expression of CRP was relatively higher in COVID-19 IgG positive individuals (7.95±12.5 mg/L) than negative individuals (6.26±6.92 mg/L; p=0.37). The rate of IgG and IgM SARS-CoV-2 immunoglobulin carriage (18%), accompanied by a relatively high CRP levels, was revealed in this study among PLHIV. This serologic evidence and mild inflammation suggest that Burkina Faso escaped the worst, not necessarily because there were not many SARS-CoV-2 infections in its population, but because factors including genetic and environmental, might have resulted in many asymptomatic carriers.
Collapse
|
6
|
Lallogo TD, Djigma FW, Sorgho PA, Martinson JJ, Rebeca Compaore T, Traore L, Bado P, Bapio Valérie Elvira Jean Télesphore Bazie, Amegnona LJ, Kagone TS, Alice Ouedraogo R, Ilboudo DP, Obiri-Yeboah D, Yonli AT, Simpore J. KIR2DL5B and HLA DRB1*12 alleles seems to be associated with protection against HIV-1 in serodiscordant couples in Burkina Faso. J Med Virol 2022; 94:4425-4432. [PMID: 35501290 DOI: 10.1002/jmv.27821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 04/25/2022] [Accepted: 04/28/2022] [Indexed: 11/05/2022]
Abstract
INTRODUCTION The Human Immunodeficiency Virus (HIV) belongs to the Retroviridae family and remains a public health problem in sub-Saharan Africa. Recent reports from WHO have shown that 33 million people died from HIV infections. HIV is one of the most serious fatal human diseases of the 20th and 21st centuries. However, variations in genetic and immunological factors are associated with protection against HIV infection in uninfected people exposed to HIV. This is the case with Naturals Killers which play an important role in the progression or regression of HIV infection. The objective of this study is to characterize certain HLA (Human Leukocyte Antigen) class II genes and KIR genes in HIV-1 serodiscordant couples in Burkina Faso. METHODS This study was carried out at Burkina Faso among nineteen (19) HIV-1 serodiscordant couples. Classical multiplex PCR (SSP-PCR) was used to characterize the presence or absence of the KIR genes and certain class II HLAs (DRB1*11 and DRB1*12). RESULTS The characterization of the KIR and HLA genes DRB1*11, DRB1*12 in this study demonstrated that the inhibitor KIR2DL5B, would confer protection against HIV-1 infection in seronegative partners [OR = 0.13 (0.02-0.72) and p = 0.029)], and the HLA DRB1*12 allele was associated with protection against HIV-1 infection in seronegative partners [OR = 0.16 (0.03-0.77) and p = 0.038]. AA and Bx haplotypes were not found to be associated with HIV-1 infection in serodiscordant couples. CONCLUSION This study confirms the involvement of the KIR genes in viral pathologies such as HIV-1 infection. Future larger-scale studies may provide a better understanding of the molecular mechanism by which the KIR Haplotype and combination of KIR/HLA are associated with protection against HIV infection. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Tatiana Doriane Lallogo
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso
| | - Florencia W Djigma
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), PO Box 364, Ouagadougou, 01, Burkina Faso
| | - Pegdwendé Abel Sorgho
- Pietro Annigoni Biomolecular Research Center (CERBA), PO Box 364, Ouagadougou, 01, Burkina Faso
| | - Jeremy James Martinson
- Laboratory of Infectious Diseases/Microbiology, University of Pittsburgh, Pittsburgh, USA
| | - T Rebeca Compaore
- Institute for Research in Health Sciences, IRSS, Ouagadougou, Burkina Faso
| | - Lassina Traore
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso
| | - Prosper Bado
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso
| | | | - Lanyo Jospin Amegnona
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso
| | - Thérèse S Kagone
- National Institute of Public Health, Center Muraz, 01 BP 390 Bobo-Dioulasso 01, Burkina Faso
| | - R Alice Ouedraogo
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso
| | | | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, PMB, Cape Coast, Ghana
| | - Albert Théophane Yonli
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), PO Box 364, Ouagadougou, 01, Burkina Faso
| | - Jacques Simpore
- Molecular Biology and Genetics Laboratory (LABIOGENE), Department of Biochemistry and Microbiology, University Joseph KI-ZERBO, PO Box 7021, Ouagadougou, 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), PO Box 364, Ouagadougou, 01, Burkina Faso
| |
Collapse
|
7
|
Barré T, Mercié P, Lions C, Miailhes P, Zucman D, Aumaître H, Esterle L, Sogni P, Carrieri P, Salmon-Céron D, Marcellin F, Salmon D, Wittkop L, Sogni P, Esterle L, Trimoulet P, Izopet J, Serfaty L, Paradis V, Spire B, Carrieri P, Valantin MA, Pialoux G, Chas J, Poizot-Martin I, Barange K, Naqvi A, Rosenthal E, Bicart-See A, Bouchaud O, Gervais A, Lascoux-Combe C, Goujard C, Lacombe K, Duvivier C, Neau D, Morlat P, Bani-Sadr F, Meyer L, Boufassa F, Autran B, Roque AM, Solas C, Fontaine H, Costagliola D, Piroth L, Simon A, Zucman D, Boué F, Miailhes P, Billaud E, Aumaître H, Rey D, Peytavin G, Petrov-Sanchez V, Levier A, Usubillaga R, Terris B, Tremeaux P, Katlama C, Valantin MA, Stitou H, Cacoub P, Nafissa S, Benhamou Y, Charlotte F, Fourati S, Zaegel O, Laroche H, Tamalet C, Callard P, Bendjaballah F, Le Pendeven C, Marchou B, Alric L, Metivier S, Selves J, Larroquette F, Rio V, Haudebourg J, Saint-Paul MC, De Monte A, Giordanengo V, Partouche C, Martin A, Ziol M, Baazia Y, Iwaka-Bande V, Gerber A, Uzan M, Garipuy D, Ferro-Collados MJ, Nicot F, Yazdanpanah Y, Adle-Biassette H, Alexandre G, Molina JM, Bertheau P, Chaix ML, Delaugerre C, Maylin S, Bottero J, Krause J, Girard PM, Wendum D, Cervera P, Adam J, Viala C, Vittecocq D, Quertainmont Y, Teicher E, Pallier C, Lortholary O, Rouzaud C, Lourenco J, Touam F, Louisin C, Avettand-Fenoel V, Gardiennet E, Mélard A, Ochoa A, Blanchard E, Castet-Lafarie S, Cazanave C, Malvy D, Dupon M, Dutronc H, Dauchy F, Lacaze-Buzy L, Desclaux A, Bioulac-Sage P, Reigadas S, Lacoste D, Bonnet F, Bernard N, Hessamfar M, J, Paccalin F, Martell C, Pertusa MC, Vandenhende M, Mercié P, Pistone T, Receveur MC, Méchain M, Duffau P, Rivoisy C, Faure I, Caldato S, Bellecave P, Tumiotto C, Pellegrin JL, Viallard JF, Lazzaro E, Greib C, Majerholc C, Brollo M, Farfour E, Devoto JP, Kansau I, Chambrin V, Pignon C, Berroukeche L, Fior R, Martinez V, Abgrall S, Favier M, Deback C, Lévy Y, Dominguez S, Lelièvre JD, Lascaux AS, Melica G, Raffi F, Allavena C, Reliquet V, Boutoille D, Biron C, Lefebvre M, Hall N, Bouchez S, Rodallec A, Le Guen L, Hemon C, Peyramond D, Chidiac C, Ader F, Biron F, Boibieux A, Cotte L, Ferry T, Perpoint T, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Amiri M, Valour F, Augustin-Normand C, Scholtes C, Le-Thi TT, Van Huyen PCMD, Buisson M, Waldner-Combernoux A, Mahy S, Rousseau AS, Martins C, Galim S, Lambert D, Nguyen Y, Berger JL, Hentzien M, Brodard V, Partisani M, Batard ML, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Fischer P, Gantner P, Fafi-Kremer S, Roustant F, Platterier P, Kmiec I, Traore L, Lepuil S, Parlier S, Sicart-Payssan V, Bedel E, Anriamiandrisoa S, Pomes C, Mole M, Bolliot C, Catalan P, Mebarki M, Adda-Lievin A, Thilbaut P, Ousidhoum Y, Makhoukhi FZ, Braik O, Bayoud R, Gatey C, Pietri MP, Le Baut V, Rayana RB, Bornarel D, Chesnel C, Beniken D, Pauchard M, Akel S, Lions C, Ivanova A, Ritleg AS, Debreux C, Chalal L, Zelie J, Hue H, Soria A, Cavellec M, Breau S, Joulie A, Fisher P, Gohier S, Croisier-Bertin D, Ogoudjobi S, Brochier C, Thoirain-Galvan V, Le Cam M, Chalouni M, Conte V, Dequae-Merchadou L, Desvallees M, Gilbert C, Gillet S, Knight R, Lemboub T, Marcellin F, Michel L, Mora M, Protopopescu C, Roux P, Tezkratt S, Barré T, Rojas TR, Baudoin M, Di Beo MSV, Nishimwe M. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data). AIDS Res Ther 2022; 19:15. [PMID: 35292069 PMCID: PMC8922772 DOI: 10.1186/s12981-022-00440-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 03/06/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Thanks to direct-acting antivirals, hepatitis C virus (HCV) infection can be cured, with similar rates in HCV-infected and HIV-HCV co-infected patients. HCV cure is likely to foster behavioral changes in psychoactive substance use, which is highly prevalent in people living with HIV (PLWH). Cannabis is one substance that is very commonly used by PLWH, sometimes for therapeutic purposes. We aimed to identify correlates of cannabis use reduction following HCV cure in HIV-HCV co-infected cannabis users and to characterize persons who reduced their use. METHODS We used data collected on HCV-cured cannabis users in a cross-sectional survey nested in the ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients, to perform logistic regression, with post-HCV cure cannabis reduction as the outcome, and socio-behavioral characteristics as potential correlates. We also characterized the study sample by comparing post-cure substance use behaviors between those who reduced their cannabis use and those who did not. RESULTS Among 140 HIV-infected cannabis users, 50 and 5 had reduced and increased their use, respectively, while 85 had not changed their use since HCV cure. Cannabis use reduction was significantly associated with tobacco use reduction, a decrease in fatigue level, paying more attention to one's dietary habits since HCV cure, and pre-HCV cure alcohol abstinence (p = 0.063 for alcohol use reduction). CONCLUSIONS Among PLWH using cannabis, post-HCV cure cannabis reduction was associated with tobacco use reduction, improved well-being, and adoption of healthy behaviors. The management of addictive behaviors should therefore be encouraged during HCV treatment.
Collapse
|
8
|
Ilboudo DP, Zohoncon TM, Hien YE, Ouattara AK, Traore L, Ouermi D, Djigma WF, Nadembega CM, Belemgnegre M, Ouedraogo P, Karou DS, Traore Y, Simpore J. Dengue Immunological Markers Evolution at Saint Camille Hospital in Ouagadougou (HOSCO) Burkina Faso. Pak J Biol Sci 2022; 25:254-262. [PMID: 35234016 DOI: 10.3923/pjbs.2022.254.262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
<b>Background and Objective:</b> Dengue is a remerging vector-borne viral disease in Burkina Faso since the outbreak of 2013 and requires special attention from health authorities. This study reports the prevalence of dengue fever serological markers (NS1Ag, IgM and IgG) and infection dynamic from January, 2018 to December, 2020 among patients tested for dengue infection at Saint Camille Hospital of Ouagadougou (HOSCO). <b>Materials and Methods:</b> The study population consisted of 6414 patients aged 0-97 years. Dengue virus infection was detected in serum or plasma using the SD bioline dengue duo rapid detection kit. <b>Results:</b> The prevalence of dengue NS1Ag was 2.25% (45/2003), 18.43% (501/2719) and 2.42% (38/1569) in the study population in 2018, 2019 and 2020, respectively. The age groups over 50 years and 15-20 years were significantly more infected compared to the group 21-30 years respectively in 2019 (p = 0.030) and 2020 (p = 0.035). Patients tested positive for at least one of these markers (NSlAg, IgG and IgM) represented 26.01% (521/2003) and 38.98% (1060/2719). The peak of infection during 2018 and 2019 was observed between October and November. The present study reports a high seroprevalence of acute dengue virus infection. The presence of NS1Ag, IgM and IgG in patients suggests an active circulation of the dengue virus in Ouagadougou. <b>Conclusion:</b> Data shows recurrent outbreaks of dengue infection in our country need strong surveillance and a suitable and affordable diagnostic system to clarify the burden, pinpoint the risk factors and for better case management.
Collapse
|
9
|
Napo A, Aboubakar H, Sidibe M, Tounkara CFM, Konaté D, Nadio T, Coulibaly A, Togo M, Sidibe F, Boro A, Keita F, Sylla F, Traore L, Le Mer Y, Cochereau I, Nordmann JP. [Efficacy and tolerance of Latanoprost given as a first intention in the treatment of primitive open angle glaucoma in African melanoderm]. J Fr Ophtalmol 2021; 44:1223-1228. [PMID: 34281763 DOI: 10.1016/j.jfo.2021.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 12/24/2020] [Accepted: 01/04/2021] [Indexed: 10/20/2022]
Abstract
OBJECTIVE To assess the reduction in IOP and ocular symptoms in patients newly diagnosed with POAG and treated with latanoprost as monotherapy. PATIENTS AND METHOD A multicentric, cross-sectional, descriptive study was conducted. We included adults newly diagnosed with POAG. All patients received one drop of preserved latanoprost 0.005% in each eye every night for 12 weeks. Changes in IOP and ophthalmic signs and symptoms were assessed during and at the end of treatment. RESULTS A total of 524 patients were included, with a participation rate of 93% at 12 weeks. The mean age was 52.79±17.33 years, and the sex ratio M/F was 1.39. At inclusion, the mean IOP was 21.68±9.72mmHg. After 2 weeks of treatment, the mean IOP was 15.49±5.81mmHg, for a reduction of 28.55%. After 12 weeks of treatment, the mean IOP was 13.16±3.54mmHg, for a reduction of 39.30%. The main symptom recorded was a gritty foreign body sensation, the frequency of which was 4.72% at W2 and 2.45% at W12. The main sign was hyperemia (4.33% at W2 and 1.84% at W12). CONCLUSION Latanoprost given as first-line monotherapy in POAG in blacks considerably reduces IOP. The incidence of side effects remains low; it is higher at the start of treatment.
Collapse
Affiliation(s)
- A Napo
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali.
| | - H Aboubakar
- Faculté de médecine et des sciences pharmaceutiques, université de Douala, Douala, Cameroun
| | - M Sidibe
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - C F M Tounkara
- Centre de Santé de Référence de la Commune III et de la Commune IV
| | - D Konaté
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - T Nadio
- Centre de Santé de Référence de la Commune III et de la Commune IV
| | - A Coulibaly
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - M Togo
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - F Sidibe
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - A Boro
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - F Keita
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - F Sylla
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - L Traore
- IOTA, université des sciences, des techniques et des technologies de Bamako, Bamako, Mali
| | - Y Le Mer
- Fondation ophtalmologique Adolphe-Rothschild, Paris, France
| | - I Cochereau
- Fondation ophtalmologique Adolphe-Rothschild, Paris, France
| | | |
Collapse
|
10
|
Lapierre J, Aboulhouda I, Gaudreault-Belley M, Ramdé J, Coté A, Bationo F, Dabal M, Beogo I, Traore L. Community-based health agents practices in Burkina Faso. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
It is estimated that around 25% of the world's infant mortality is in West Africa where undernutrition accounts for more than 50% of the underlying causes of under-5 mortality. Malnutrition rates have decreased slightly, especially compared to the targets set for 2025. Since Alma-Ata's declaration in 1978, community participation in primary health care has been one way of reducing health inequalities. WHO recommended the integration of community health workers (CHW) into the health system and their inclusion in the human resources planning strategy. We observed a decline of programs involving CHW in the 1990s, then a definite revaluation since the 1990s and specifically, since 2012. They provide health education, as well as referral for a range of services, and provide support and assistance to communities and families through preventive health, easier access to curative health services as well as social services. The specific objectives of this project include: to describe the roles and functions of CHW in Burkina Faso, to identify the workers' needs, to explore the changes in the system and to identify the conditions related to their deployment.
Methods
A qualitative case study allowed to describe the processes and also facilitated the discovery of key elements related to the experiences of community agents, considering the elements of complexity and context.
Results
Our results include activities in promotional services, preventive services, curative services and health data management. In addition, we will shed light on their feelings and experiences related to integration into the system, on the strategies they use, on the advantages that bring their role as community workers, their concerns and finally, we will share their perception of their impact. Some recommendations are proposed in regards to training and supervision.
Key messages
CHW are major players in health systems by creating a bridge between health and social service providers and communities with reduced access. CHW contributes to social justice by facilitating access, promoting recognition and creating empowering processes through increased participation.
Collapse
Affiliation(s)
- J Lapierre
- Faculté des Sciences infirmières, Université Laval, Québec, Canada
| | - I Aboulhouda
- Faculté des Sciences infirmières, Université Laval, Québec, Canada
| | | | - J Ramdé
- Faculté des Sciences de l'éducation, Université Laval, Québec, Canada
| | - A Coté
- Faculté des Sciences de l'administration, Université Laval, Québec, Canada
| | - F Bationo
- Faculté de Sociologie, Université de Ouagadougou, Ouagadougou, Burkina Faso
| | - M Dabal
- Santé, Entraide universitaire mondiale, Ouagadougou, Burkina Faso
| | - I Beogo
- Faculté des Sciences de l'administration, Université Laval, Québec, Canada
| | - L Traore
- Santé, Entraide universitaire mondiale, Ouagadougou, Burkina Faso
| |
Collapse
|
11
|
Marcellin F, Di Beo V, Aumaitre H, Mora M, Wittkop L, Duvivier C, Protopopescu C, Lacombe K, Esterle L, Berenger C, Gilbert C, Bouchaud O, Poizot-Martin I, Sogni P, Salmon-Ceron D, Carrieri P, Wittkop L, Sogni P, Esterle L, Trimoulet P, Izopet J, Serfaty L, Paradis V, Spire B, Carrieri P, Valantin M, Pialoux G, Chas J, Poizot-Martin I, Barange K, Naqvi A, Rosenthal E, Bicart-See A, Bouchaud O, Gervais A, Lascoux-Combe C, Goujard C, Lacombe K, Duvivier C, Neau D, Morlat P, Bani-Sadr F, Meyer L, Boufassa F, Autran B, Roque A, Solas C, Fontaine H, Costagliola D, Piroth L, Simon A, Zucman D, Boué F, Miailhes P, Billaud E, Aumaître H, Rey D, Peytavin G, Petrov-Sanchez V, Lebrasseur-Longuet D, Salmon D, Usubillaga R, Sogni P, Terris B, Tremeaux P, Katlama C, Valantin M, Stitou H, Simon A, Cacoub P, Nafissa S, Benhamou Y, Charlotte F, Fourati S, Poizot-Martin I, Zaegel O, Laroche H, Tamalet C, Pialoux G, Chas J, Callard P, Bendjaballah F, Amiel C, Le Pendeven C, Marchou B, Alric L, Barange K, Metivier S, Selves J, Larroquette F, Rosenthal E, Naqvi A, Rio V, Haudebourg J, Saint-Paul M, De Monte A, Giordanengo V, Partouche C, Bouchaud O, Martin A, Ziol M, Baazia Y, Iwaka-Bande V, Gerber A, Uzan M, Bicart-See A, Garipuy D, Ferro-Collados M, Selves J, Nicot F, Gervais A, Yazdanpanah Y, Adle-Biassette H, Alexandre G, Peytavin G, Lascoux-Combe C, Molina J, Bertheau P, Chaix M, Delaugerre C, Maylin S, Lacombe K, Bottero J, Krause J, Girard P, Wendum D, Cervera P, Adam J, Viala C, Vittecocq D, Goujard C, Quertainmont Y, Teicher E, Pallier C, Lortholary O, Duvivier C, Rouzaud C, Lourenco J, Touam F, Louisin C, Avettand-Fenoel V, Gardiennet E, Mélard A, Neau D, Ochoa A, Blanchard E, Castet-Lafarie S, Cazanave C, Malvy D, Dupon M, Dutronc H, Dauchy F, Lacaze-Buzy L, Desclaux A, Bioulac-Sage P, Trimoulet P, Reigadas S, Morlat P, Lacoste D, Bonnet F, Bernard N, Hessamfar, J M, Paccalin F, Martell C, Pertusa M, Vandenhende M, Mercié P, Malvy D, Pistone T, Receveur M, Méchain M, Duau P, Rivoisy C, Faure I, Caldato S, Bioulac-Sage P, Trimoulet P, Reigadas S, Bellecave P, Tumiotto C, Pellegrin J, Viallard J, Lazzaro E, Greib C, Bioulac-Sage P, Trimoulet P, Reigadas S, Zucman D, Majerholc C, Brollo M, Farfour E, Boué F, Polo Devoto J, Kansau I, Chambrin V, Pignon C, Berroukeche L, Fior R, Martinez V, Abgrall S, Favier M, Deback C, Lévy Y, Dominguez S, Lelièvre J, Lascaux A, Melica G, Billaud E, Raffi F, Allavena C, Reliquet V, Boutoille D, Biron C, Lefebvre M, Hall N, Bouchez S, Rodallec A, Le Guen L, Hemon C, Miailhes P, Peyramond D, Chidiac C, Ader F, Biron F, Boibieux A, Cotte L, Ferry T, Perpoint T, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Amiri M, Valour F, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Augustin-Normand C, Scholtes C, Le-Thi T, Piroth L, Chavanet P, Duong Van Huyen M, Buisson M, Waldner-Combernoux A, Mahy S, Binois R, Simonet-Lann A, Croisier-Bertin D, Salmon Rousseau A, Martins C, Aumaître H, Galim S, Bani-Sadr F, Lambert D, Nguyen Y, Berger J, Hentzien M, Brodard V, Rey D, Partisani M, Batard M, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Gantner et S Fafi-Kremer P, Roustant F, Platterier P, Kmiec I, Traore L, Lepuil S, Parlier S, Sicart-Payssan V, Bedel E, Anriamiandrisoa S, Pomes C, Touam F, Louisin C, Mole M, Bolliot C, Catalan P, Mebarki M, Adda-Lievin A, Thilbaut P, Ousidhoum Y, Makhoukhi F, Braik O, Bayoud R, Gatey C, Pietri M, Le Baut V, Ben Rayana R, Bornarel D, Chesnel C, Beniken D, Pauchard M, Akel S, Caldato S, Lions C, Ivanova A, Ritleg AS, Debreux C, Chalal L, Zelie J, Hue H, Soria A, Cavellec M, Breau S, Joulie A, Fisher P, Gohier S, Croisier-Bertin D, Ogoudjobi S, Brochier C, Thoirain-Galvan V, Le Cam M, Carrieri P, Chalouni M, Conte V, Dequae-Merchadou L, Desvallees M, Esterle L, Gilbert C, Gillet S, Knight R, Lemboub T, Marcellin F, Michel L, Mora M, Protopopescu C, Roux P, Spire B, Tezkratt S, Barré T, Baudoin M, Santos M, Di Beo V, Nishimwe M, Wittkop L. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH). J Hepatol 2020; 72:588-591. [PMID: 31924411 DOI: 10.1016/j.jhep.2019.10.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 10/17/2019] [Accepted: 10/25/2019] [Indexed: 01/26/2023]
Affiliation(s)
- Fabienne Marcellin
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.
| | - Vincent Di Beo
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Hugues Aumaitre
- Infectious and Tropical Disease Unit, Perpignan Hospital Center, Perpignan, France
| | - Marion Mora
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Linda Wittkop
- Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France; CHU de Bordeaux, Pole de santé publique, F-33000 Bordeaux, France
| | - Claudine Duvivier
- AP-HP-Necker Hospital, Infectious Diseases Department, Necker-Pasteur Infectiology Center, IHU Imagine, Université de Paris, INSERM, U1016, Institut Cochin, CNRS, UMR8104, Paris, France; Institut Pasteur, Medical Center of Institut Pasteur, Necker-Pasteur Infectiology Center, Paris, France
| | - Camelia Protopopescu
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Karine Lacombe
- Infectious and Tropical Disease Unit, Paris Public Hospitals, Saint-Antoine Hospital, Paris, France; UMR S1136, Pierre Louis Epidemiology and Public Health Institute, Pierre and Marie Curie University, Paris, France
| | - Laure Esterle
- Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France
| | - Cyril Berenger
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Camille Gilbert
- Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France
| | - Olivier Bouchaud
- Infectious and Tropical Disease Unit, Paris Publics Hospitals, Avicenne Hospital, Bobigny, France; Paris 13 Nord University, Bobigny, France
| | - Isabelle Poizot-Martin
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; APHM Sainte-Marguerite, Clinical Immunohematology Unit, Aix Marseille University, Marseille, France
| | - Philippe Sogni
- Université Paris Descartes, Paris, France; INSERM U-1223, Institut Pasteur, Paris, France; Service d'Hépatologie, hôpital Cochin, Assistance Publique - Hôpitaux de Paris, France
| | - Dominique Salmon-Ceron
- Université Paris Descartes, Paris, France; Service Maladies infectieuses et tropicales, AP-HP, Hôpital Cochin, Paris, France
| | - Patrizia Carrieri
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Sorgho PA, Djigma FW, Martinson JJ, Yonli AT, Nagalo BM, Compaore TR, Diarra B, Sombie HK, Simpore A, Zongo AW, Ouattara AK, Soubeiga STR, Traore L, Yelemkoure ET, Kiendrebeogo IT, Roberts LR, Simpore J. Role of Killer cell immunoglobulin-like receptors (KIR) genes in stages of HIV-1 infection among patients from Burkina Faso. Biomol Concepts 2019; 10:226-236. [PMID: 31863692 DOI: 10.1515/bmc-2019-0024] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 11/14/2019] [Indexed: 12/16/2022] Open
Abstract
Objectives A cluster of specialized KIR genes of specialized KIR genes has been shown to be associated with susceptibility or resistance to viral infections in humans. Therefore, this pilot study, this pilot investigation sought to determine the frequencies of KIR genes human immunodeficiency virus type 1( HIV-1) patients and establish their potential clinical involvement in disease progression and staging. Methods HIV-1 infected and healthy individuals were selected for this study. Hepatitis B surface antigen (HBsAg), anti-HCV antibodies and anti-HIV-1/2 antibody/ antigen were screened using a 4th generation ELISA assay (Cobas e 411 Analyzer, Roche Diagnostics GmbH Mannheim, Germany). SSP-PCR was used to evaluate the frequencies of KIR genes. CD4+ T counts and HIV-1 viral load were measured in patients using respectively BD FACSCount and Abbott m2000rt instruments. Results We found a significant association between the frequencies of KIR2DL2 (OR=4.41; p < 0.001), KIR2DS2 (OR=4.76; p < 0.001), KIR2DS3 (OR=2.27; p=0.004), KIR2DS4 (OR=1.76; p=0.026), KIR3DS1 (OR=2.43; p=0.016) and HIV-1 infection; whilst the KIR3DL1 gene (OR= 0.39; p < 0.001) was associated with protection against HIV-1 infection. HIV-1 replication was found to be associated with the presence of KIR2DS2 (OR=6.08, p = 0.024). In contrary the pseudogene KIR2DP1 (OR=0.39; p=0.026) were linked to a protective status with the highest number of lymphocyte T CD4 counts. Conclusion Our data showed that KIR2DL2, KIR2DS2, KIR2DS3, KIR2DS4, and KIR3DS1 were significantly associated with HIV-1 infection whereas KIR3DL1 was associated with protection against HIV-1 infection. Further investigations are needed to fully comprehend the clinical significance of KIR genes in HIV disease progression.
Collapse
Affiliation(s)
- Pegdwendé Abel Sorgho
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Jeremy James Martinson
- Laboratory of Infectious Diseases/ Microbiology, University of Pittsburgh, Pittsburgh, USA
| | - Albert Théophane Yonli
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Bolni Marius Nagalo
- Division of Hematology & Oncology, Mayo Clinic, Arizona, Scottsdale Arizona, USA
| | - Tégwindé Rebeca Compaore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Institut de Recherche en Sciences de la Sante, IRSS, Ouagadougou, Burkina Faso
| | - Birama Diarra
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Herman Karim Sombie
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Abibou Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Arsène Wendpagnangdé Zongo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Serge Théophile R Soubeiga
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Lassina Traore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Edwige T Yelemkoure
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Isabelle Touwendpoulimdé Kiendrebeogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Lewis R Roberts
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota,USA
| | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| |
Collapse
|
13
|
Napo A, Guirou N, Boro A, Dougnon A, Keita F, Simaga A, Sylla F, Théra J, Traore L, Bamani S. [Evaluation of the quality of life of adult patients treated in low vision at the CHU-IOTA]. J Fr Ophtalmol 2019; 42:492-498. [PMID: 30987760 DOI: 10.1016/j.jfo.2019.01.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 10/28/2018] [Accepted: 01/22/2019] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Visual impairment is a handicap defined as any alteration of visual function responsible for a partial or total limitation of the activities of daily living (OMS, 2004). The objective of this study is to assess quality of life in patients before and after management of low vision. PATIENTS AND METHODS This was a mono-centric, transverse, analytical study over a period of 6 months. Our study population included all adult patients seen in ophthalmologic consultation and followed in the low vision unit with visual acuity less than 3/10 and greater than or equal to 1/20 in the best eye with best optical correction. The National Eye Institute's quality of life questionnaire, the NEF VFQ 25, was administered to patients on site prior to management and then a month later. RESULTS Low-vision management improved overall the dimensions of the quality of life questionnaire. Following the end-of-care assessment, the score for ocular pain was lowest (38.20), followed by the overall vision score (44.95) and near vision difficulty score (45.33). DISCUSSION Our sample population was distinguished by a cultural mix, with diversity of beliefs and lifestyles, and also by the relatively advanced age of the subjects constituting it. This can influence the individual's perception of him- or herself within his or her environment, modifying the patient's estimation of his or her condition and therefore his or her behavior. CONCLUSION Low-vision rehabilitation can improve the quality of life of visually impaired patients, particularly for near vision, activities of daily living and psychological health.
Collapse
Affiliation(s)
- A Napo
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali.
| | - N Guirou
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - A Boro
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - A Dougnon
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - F Keita
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - A Simaga
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - F Sylla
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - J Théra
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - L Traore
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| | - S Bamani
- Institut d'ophtalmologie tropicale de l'Afrique, BP 248, Bamako, Mali
| |
Collapse
|
14
|
Napo A, Guirou N, Fofana Y, Sidibe M, Bogoreh R, Keita F, Thera JP, Traore L. [Giant eyelid tumor]. J Fr Ophtalmol 2019; 42:425-426. [PMID: 30879834 DOI: 10.1016/j.jfo.2018.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 08/24/2018] [Accepted: 09/03/2018] [Indexed: 11/19/2022]
Affiliation(s)
- A Napo
- Institut d'Ophtalmologie Tropicale de l'Afrique de Bamako, BP 248, Bamako, Mali.
| | - N Guirou
- Institut d'Ophtalmologie Tropicale de l'Afrique de Bamako, BP 248, Bamako, Mali
| | - Y Fofana
- Ex Institut Marchoux, Avenue Raoul-Follereau, Djikoroni Para, 251 Bamako, Mali
| | - M Sidibe
- Hôpital régional de Sikasso, BP 82, Sikasso, Mali
| | - R Bogoreh
- Institut d'Ophtalmologie Tropicale de l'Afrique de Bamako, BP 248, Bamako, Mali
| | - F Keita
- Institut d'Ophtalmologie Tropicale de l'Afrique de Bamako, BP 248, Bamako, Mali
| | - J P Thera
- Institut d'Ophtalmologie Tropicale de l'Afrique de Bamako, BP 248, Bamako, Mali
| | - L Traore
- Programme National de Santé Oculaire, BP 228, Bamako, Mali
| |
Collapse
|
15
|
Diarra B, Yonli AT, Ouattara AK, Zohoncon TM, Traore L, Nadembega C, Obiri-Yeboah D, Yara J, Pietra V, Ouedraogo P, Bougouma A, Sanogo R, Simpore J. World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal. Virol J 2018; 15:121. [PMID: 30081915 PMCID: PMC6080359 DOI: 10.1186/s12985-018-1032-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 07/26/2018] [Indexed: 01/28/2023] Open
Abstract
Background Burkina Faso is a high endemicity country for HBV infection. However, there are few data on vaccine coverage against HBV. The aim of this study was to contribute to the improvement of HBV vaccine coverage in Ouagadougou through HBV screening. Methods Awareness campaigns and voluntary hepatitis B screening were organized in the twelve districts of Ouagadougou by the “SOS Hepatitis Burkina” association. A rapid HBsAg detection test (Abon Biopharma Guangzhou, Co., Ltd. Chine) was performed on 2216 individuals, who voluntarily answered a series of questions. Vaccination against hepatitis B was proposed to HBV negative participants. Results In a sample of 2216 participants, aged 1 to 78 years (mean age 29.7 ± 14.7 years); a prevalence of 10.4% (230/2216) of HBsAg was obtained. This prevalence was high in the age groups 31 to 40 years (14.5%) and 41 to 50 years (15.0%). The prevalence of HBV was higher in the sixth district (14.3%) of Ouagadougou. At the end of the screening, 1202/1986 HBV negative participants were vaccinated, resulting in a vaccination rate of 60.5%. Vaccination coverage ranged from 44.5 to 73.7% all twelve districts. Conclusions This study still reports a high prevalence of HBV infection among young people with a peak in the sixth district of Ouagadougou. The study achieved high vaccination coverage in all age groups and districts of Ouagadougou. Trial registration The present study has been approved by the Ethics Committee for Health Research of Burkina Faso. CERS201501006 Registered 14 January 2015.
Collapse
Affiliation(s)
- Birama Diarra
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Albert Theophane Yonli
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Abdoul Karim Ouattara
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso. .,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso.
| | - Theodora Mahoukèdè Zohoncon
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Lassina Traore
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Christelle Nadembega
- Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Justine Yara
- SOS Hepatitis, Ouagadougou, Burkina Faso.,Saint Camille Hospital of Ouagadougou (HOSCO), BP 444, Ouagadougou 01, Burkina Faso
| | - Virginio Pietra
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso
| | - Paul Ouedraogo
- Saint Camille Hospital of Ouagadougou (HOSCO), BP 444, Ouagadougou 01, Burkina Faso
| | - Alain Bougouma
- Gastroenterology Service, CHU Yalgado OUEDRAOGO, Ouagadougou, Burkina Faso
| | - Rokia Sanogo
- Faculty of Pharmacy, University of Technical Sciences and Technologies of Bamako (USTTB), Bamako, Mali
| | - Jacques Simpore
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso.,Saint Camille Hospital of Ouagadougou (HOSCO), BP 444, Ouagadougou 01, Burkina Faso
| |
Collapse
|
16
|
Soubeiga ST, Bazie BVJTE, Compaore TR, Ouattara AK, Zohoncon TM, Obiri-Yeboah D, Yonli AT, Zongo A, Traore L, Pietra V, Akpona S, Diagbouga S, Simpore J. Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso. J Public Health Afr 2018; 9:767. [PMID: 30079168 PMCID: PMC6057714 DOI: 10.4081/jphia.2018.767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Accepted: 02/19/2018] [Indexed: 11/23/2022] Open
Abstract
The emergence of HIV-1 drug resistance (HIVDR) is a public health problem that affects women and children. Local data of HIVDR is critical to improving their care and treatment. So, we investigated HIVDR in mothers and infants receiving antiretroviral therapy (ART) at Saint Camille Hospital of Ouagadougou, Burkina Faso. This study included 50 mothers and 50 infants on ART. CD4 and HIV-1 viral load were determined using FACSCount and Abbott m2000rt respectively. HIVDR was determined in patients with virologic failure using ViroSeq HIV-1 Genotyping System kit on the 3130 Genetic Analyzer. The median age was 37.28 years in mothers and 1.58 year in infants. Sequencing of samples showed subtypes CRF02_AG (55.56%), CRF06_cpx (33.33%) and G (11.11%). M184V was the most frequent and was associated with highlevel resistance to 3TC, FTC, and ABC. Other mutations such as T215F/Y, D67N/E, K70R, and K219Q were associated with intermediate resistance to TDF, AZT, and 3TC. No mutation to LPV/r was detected among mothers and infants. The findings of HIVDR in some mothers and infants suggested the change of treatment for these persons.
Collapse
Affiliation(s)
- Serge Théophile Soubeiga
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | | | - Tegwindé Rebeca Compaore
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Théodora Mahoukèdè Zohoncon
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana
| | - Albert Théophane Yonli
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Arsène Zongo
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Lassina Traore
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Virginio Pietra
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | | | - Serge Diagbouga
- Research Institute for Health Sciences, Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| |
Collapse
|
17
|
Ouattara AK, Yameogo P, Traore L, Diarra B, Assih M, Compaore TR, Obiri-Yeboah D, Soubeiga ST, Djigma FW, Simpore J. Prevalence, genetic variants and clinical implications of G-6-PD deficiency in Burkina Faso: a systematic review. BMC Med Genet 2017; 18:139. [PMID: 29169341 PMCID: PMC5701495 DOI: 10.1186/s12881-017-0496-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/12/2017] [Accepted: 11/09/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND It is now well-known that some antimalarials such as primaquine may induce severe hemolytic anemia in people with G-6-PD deficiency. Antimalarial drug prescriptions must, therefore take into account the patient's G-6-PD status in malaria endemic areas such as Burkina Faso, where the prevalence of this genetic abnormality is relatively high. Although great clinical heterogeneity is observed depending on the molecular nature of the deficiency and the residual enzyme activity in the red blood cell, there is very poor data on the prevalence of G-6-PD deficiency and the distribution of involved genetic variants in Burkina Faso. In this systematic review, we present a synthesis of the various studies carried out on the G-6-PD deficiency in Burkina Faso in order to determine its prevalence, probable distribution of the genetic variants involved and their clinical implications for a national systematic screening policy among the groups most vulnerable to malaria. METHODS A systematic review was carried out to analyze available published data on the prevalence, phenotypes and mutations responsible for G-6-PD deficiency in Burkina Faso. The key words used were "G-6-PD deficiency AND Burkina Faso" or "Déficit en G-6-PD AND Burkina Faso" in French. To identify the relevant articles, two independent reviewers reviewed the titles, abstracts and the full text of the selected papers. RESULTS An average prevalence of 16.6% (183/1100; CI 95%: 0.145-0.190) and 6.5% (69/1066; CI 95%: 0.051-0.081) of G-6-PD deficiency was found respectively in men and women in this systematic review. Although the predominance (99.8% of G-6-PD deficient cases) of 202A/376G G-6-PD A- variant, the Santamaria and Betica Selma variants were identified in Burkina Faso. Independently of the method used, the enzymatic deficiency was significantly higher in males (2.5-20.5%) compared to females (3.3-12.3%). CONCLUSION This systematic review suggests that despite the ubiquity of the 202A/376G G-6-PD A- variant in Burkina Faso, it will be necessary to consider the Santamaria and Betica Selma variants although their frequencies remain to be specified. A systematic screening of the G-6-PD deficiency is also needed to prevent the occurrence of iatrogenic hemolytic accidents.
Collapse
Affiliation(s)
- Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso. .,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso.
| | - Pouiré Yameogo
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Lassina Traore
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Birama Diarra
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Maléki Assih
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Tegwindé Rébéca Compaore
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, University of Cape Coast, Cape Coast, Ghana
| | - Serge Théophile Soubeiga
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| |
Collapse
|
18
|
|
19
|
Nadio T, Napo A, Balde R, Sidibe M, Conare I, Traore L, Bamani S, Traore J. [Extracting extra capsular versus phacomanuelle without sutures in the treatment of the cataract of the adult to the CHU-IOTA]. Mali Med 2017; 32:16-19. [PMID: 30079688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
INTRODUCTION Treatment of cataract blindness is surgical to restore vision. The aim of this work was to compare the PKA to the classic EEC in the surgical treatment of adult cataract in terms of anatomical and functional results in our institute. MATERIALS AND METHODS This was a cross-sectional study of 333 operated eyes of cataract of the adult and followed for one month. The postoperative functional data and the causes of poor results were specified. RESULT A total of 172 men (51.7%) and 161 women (48.3%) underwent cataract surgery. The mean age was 64.2 years. 61.26% of patients had visual acuity (≥3 / 10) in EEC compared with 65.28% in PKA. (21%) for EEC, and (15%) for PKA had poor visual acuity (<1/10). The proportion of patients with good results increases with the best correction to 77.3% for EEC and 91.5% for PKA. The poor results close to those of the WHO in both techniques (6.7%). EEC and (5.3%) PKA. The poor results were mainly related to pre-existing pathologies (6.6%) and astigmatism related to surgery (7.1%). CONCLUSION In order to achieve the objectives of "Vision 2020", within the framework of the fight against blindness, it is imperative to facilitate the popularization of the PKA throughout the African subregion.
Collapse
|
20
|
Traore L, Tao I, Bisseye C, Diarra B, Compaore TR, Nebie Y, Assih M, Ouedraogo A, Zohoncon T, Djigma F, Ouermi D, Barro N, Sanou M, Ouedraogo RT, Simpore J. Molecular diagnostic of cytomegalovirus, Epstein Barr virus and Herpes virus 6 infections among blood donors by multiplex real-time PCR in Ouagadougou, Burkina Faso. Pan Afr Med J 2016; 24:298. [PMID: 28154653 PMCID: PMC5267872 DOI: 10.11604/pamj.2016.24.298.6578] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Accepted: 07/15/2016] [Indexed: 12/21/2022] Open
Abstract
Introduction In most developing countries, Cytomegalovirus (CMV), Epstein Barr virus (EBV) and Herpes virus 6 (HHV-6) are not diagnosed in blood donors. The aim of this study is to determine the prevalence of these viruses in blood donors from the city of Ouagadougou, Burkina Faso. Methods The study included 198 blood donors of the Regional Blood Transfusion Centre of Ouagadougou. Multiplex real time PCR was used to diagnose the three viruses. Statistical analysis was performed with the software EpiInfo version 6 and SPSS version 17. P values ≤ 0.05 were considered significant. Results Of 198 samples tested, 18 (9.1%) were positive to at least one of the three viruses. In fact, 10 (5.1%) were positive for EBV, 10 (5.1%) positive for CMV and 12 (6.1%) positive for HHV-6. Viral infections were higher in women than in men, EBV (8,6% versus 4.3%), CMV (8.6% versus 3.7%) and HHV-6 (11.4% versus 4.9%). EBV / CMV / HHV-6 co-infection was found in 3.5% (7/198) of blood donors. Conclusion The prevalence recorded in this study is low compared to those found in previous studies from the sub-region among blood donors. The molecular diagnostic test used in our study could explain the differences with previous studies.
Collapse
Affiliation(s)
- Lassina Traore
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Issoufou Tao
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Cyrille Bisseye
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso; Laboratory of Molecular and Cellular Biology, University of Sciences and Techniques of Masuku, P 943 Franceville, Gabon
| | - Birama Diarra
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Tegwindé Rebeca Compaore
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Yacouba Nebie
- Molecular Biology, Epidemiology and Monitoring of Communicable of Bacteria and Viruses Through Food, UFR / SVT, University of Ouagadougou, Burkina Faso
| | - Maleki Assih
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Alice Ouedraogo
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Theodora Zohoncon
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Florencia Djigma
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Djénéba Ouermi
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Nicolas Barro
- Molecular Biology, Epidemiology and Monitoring of Communicable of Bacteria and Viruses Through Food, UFR / SVT, University of Ouagadougou, Burkina Faso
| | - Mahamoudou Sanou
- Molecular Biology, Epidemiology and Monitoring of Communicable of Bacteria and Viruses Through Food, UFR / SVT, University of Ouagadougou, Burkina Faso
| | - Rasmata Traore Ouedraogo
- Molecular Biology, Epidemiology and Monitoring of Communicable of Bacteria and Viruses Through Food, UFR / SVT, University of Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Biomolecular Research Center Pietro Annigoni Labiogene, UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| |
Collapse
|
21
|
Ouedraogo AR, Kabre M, Bisseye C, Zohoncon TM, Asshi M, Soubeiga ST, Diarra B, Traore L, Djigma FW, Ouermi D, Pietra V, Barro N, Simpore J. [Molecular tests in diagnosis of Cytomegalovirus (CMV), human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) using real-time PCR in HIV positive and HIV-negative pregnant women in Ouagadougou, Burkina Faso]. Pan Afr Med J 2016; 24:223. [PMID: 27800078 PMCID: PMC5075482 DOI: 10.11604/pamj.2016.24.223.9406] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Accepted: 05/23/2016] [Indexed: 11/13/2022] Open
Abstract
Introduction Les herpès virus EBV, CMV et HHV-6 sont des virus qui évoluent sous le modèle pandémique et sont responsables d’infections congénitales pouvant provoquer des séquelles graves chez les nouveau-nés. L’objectif de cette étude était de déterminer les prévalences de CMV, EBV et HHV-6 chez les femmes enceintes VIH(+) et VIH(-) à Ouagadougou. Méthodes Dans cette étude 200 échantillons de plasma sanguin de femmes enceintes dont 100 femmes VIH(+) et 100 femmes VIH(-) ont été diagnostiqués par PCR multiplex en temps réel pour les trois infections (EBV, CMV et HHV-6). Résultats Sur l’ensemble des 200 échantillons analysés, 18 (9,0%) étaient positifs à au moins un des trois virus, 12 (6,0%) étaient positifs au EBV, 13 (6,5%) au CMV et 12 (6,0%) positifs au HHV-6. Parmi les 18 cas d’infections, nous avons trouvé 10 cas (55,6%) de coïnfections dont 90,0% (9/10) d’infection multiple EBV/CMV/HHV6 et 10,0% de coinfection EBV/HHV6. Le taux d’infection HHVs était plus élevé chez les femmes VIH(-) que celles VIH(+) (12,0% versus 6,0%). Parmi les VIH(+), la PCR a révélé 7,1% (soit 6/85) d’infection HHVs chez celles qui n’étaient pas sous ARV contre 0% chez celles sous ARV. Conclusion Les herpès virus sont fréquents chez les femmes enceintes au Burkina Faso et pourraient constituer une menace chez ces dernières à cause des complications et des risques d’infection pour le nouveau-né.
Collapse
Affiliation(s)
- Alice Rogomenoma Ouedraogo
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Madeleine Kabre
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Cyrille Bisseye
- Laboratoire de Biologie Moléculaire et Cellulaire (LABMC), Université des Sciences et Techniques de Masuku (USTM), Franceville, Gabon
| | - Théodora Mahoukèdè Zohoncon
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Maleki Asshi
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Serge Théophile Soubeiga
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Birama Diarra
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Lassina Traore
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Djénéba Ouermi
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Virginio Pietra
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Nicolas Barro
- Laboratoire de Biologie Moléculaire, d'Epidémiologie et de Surveillance des Bactéries et virus Transmissibles par les Aliments (LaBESTA), UFR/SVT, Université de Ouagadougou
| | - Jacques Simpore
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), LABIOGENE UFR/SVT, Université de Ouagadougou BP 364 Ouagadougou, Burkina Faso
| |
Collapse
|
22
|
Soubeiga ST, Compaore R, Djigma F, Zagre N, Assengone E, Traore L, Diarra B, Bisseye C, Ouermi D, Sagna T, Karou S, Pietra V, Simpore J. [Evaluation of antiretroviral therapy on mother to child transmission HIV in HIV-1 positive pregnant women: case of St. Camillus Medical Center in Ouagadougou, Burkina Faso]. Pan Afr Med J 2015; 20:399. [PMID: 26301003 PMCID: PMC4524915 DOI: 10.11604/pamj.2015.20.399.5627] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Accepted: 04/01/2015] [Indexed: 11/11/2022] Open
Affiliation(s)
- Serge Theophile Soubeiga
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Rebecca Compaore
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Florencia Djigma
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Nicaise Zagre
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Elsa Assengone
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Lassina Traore
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Birama Diarra
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Cyrille Bisseye
- Département de Biologie, Faculté des Sciences Université des Sciences et Techniques de Masuku (USTM) BP 934, Franceville, Gabon
| | - Djeneba Ouermi
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Tani Sagna
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Simplice Karou
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso ; Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA-UL), Université de Lomé, Togo
| | - Virginio Pietra
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Burkina Faso
| |
Collapse
|
23
|
Aimé X, Traore L, Chniti A, Sadou E, Ouagne D, Charlet J, Jaulent MC, Darmoni S, Griffon N, Amardeilh F, Bascarane L, Lepage E, Daniel C. Semantic interoperability platform for Healthcare Information Exchange. Ing Rech Biomed 2015. [DOI: 10.1016/j.irbm.2015.01.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Doumbia-Singare K, Timbo SK, Ouattara MA, Ba B, Guindo B, Soumaoro S, Traore L, Keita M, Ag Mohamed A. [Mediastinitis complicating cervical cellulite: 8 cases observed in the ear, nose and throat department of the Gabriel Toure university hospital, Bamako (Mali)]. Mali Med 2015; 30:49-52. [PMID: 29927146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVE The objective of this work was to analyze the diagnostic circumstances and the therapeutic management of mediastinal disease of a cervical origin. PATIENTS AND METHODS We conducted a longitudinal prospective and retrospective descriptive study in the ENT department of the Gabriel Touré Hospital in Bamako, involving the records of patients treated for mediastinitis complicating cervical cellulite from January 2011 to April 2014. RESULTS Eight patients met our inclusion criteria. The median age was 29 years, the standard deviation was 10.23 years with extremes of 25 and 57 years. All were initially admitted for dental reasons. The median time to consultation was 13 days with extremes of 10 days and 1 month. Six patients had non-steroidal anti-inflammatory drugs before entry into the service. Cervical and thoracic CT scan was used to guide diagnosis in all cases. Seven patients underwent mediastinal drainage through cervicotomy, 3 patients underwent percutaneous pleural drainage under ultrasound guidance. We had two deaths. CONCLUSION Mediastinitis in cervical cellulitis is a serious infectious disease where the mortality rate remains high. Mediastinal drainage was performed by cervical route. Prevention is based on the awareness and the importance of dental hygiene and getting proper and early treatment for dental cavities.
Collapse
Affiliation(s)
- K Doumbia-Singare
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| | | | - M A Ouattara
- Service de chirurgie thoracique de l'hôpital du Mali
| | - Boubacar Ba
- CHU du CNOS (Centre National d'OdontoStomatologie)
| | | | | | | | | | | |
Collapse
|
25
|
Traore L, Tao I, Bisseye C, Djigma F, Ouermi D, Zohoncon T, Compaoré TR, Diarra B, Asshi M, Simpore J. Molecular diagnosis of cytomegalovirus, Epstein-Barr virus and Herpes virus 6 among blood donors in Ouagadougou, Burkina Faso. BMC Infect Dis 2014. [PMCID: PMC4221054 DOI: 10.1186/1471-2334-14-s2-p99] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
26
|
Timbo SK, Doumbia-Singare K, Guindo B, Soumaoro S, Traore L, Keita M, Ag MA. [Giant mucocele maxillary sinus: About a case]. Mali Med 2014; 29:59-61. [PMID: 30049104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
UNLABELLED The maxillary mucocele sinus are rare and may extend outside the sinus and cause a facial deformity and orbital manifestations. OBSERVATION We report a case of giant mucocele of the right maxillary sinus from a 48 year old man. The history of disease has found a right cheek tumefaction. hypoesthesia of the right hemifacial, nasal obstruction lasting for 2 years. CT scan of the facial confirmed diagnosis by showing a cystic mass of the right maxillairy sinus bulging into the right nasal cavity with bone thinning without bone lysis. The treatement is removal of the mucocelique pochet by Caldwell-Luc under general anesthesia and allowed disparition of symptoms. CONCLUSION Africa the Caldwell-Luc seems to us preferable because of diagnosis tardif the origin of the importance of the expansion.
Collapse
Affiliation(s)
- S K Timbo
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| | - K Doumbia-Singare
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| | - B Guindo
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| | - S Soumaoro
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| | - L Traore
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| | - M Keita
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| | - Mohamed A Ag
- Service d'ORL et de chirurgie cervico-faciale du CHU Gabriel TOURE BP 267 Bamako. Mali
| |
Collapse
|
27
|
Guirou N, Napo A, Bakayoko S, Sylla F, Dougnon A, Sidibé F, Théra PJ, Guindo A, Conaré I, Traore L, Traoré J. [Bilateral persistent fetal vasculature]. J Fr Ophtalmol 2013; 36:803-5. [PMID: 23911068 DOI: 10.1016/j.jfo.2013.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2012] [Accepted: 01/07/2013] [Indexed: 10/26/2022]
Affiliation(s)
- N Guirou
- Centre hospitalier universitaire-institut d'ophtalmologie tropicale d'Afrique (CHU-IOTA) Bamako, boulevard du Peuple, BP 248, Bamako, Mali.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Doumbia-Singare K, Timbo SK, Soumaoro S, Keita M, Guindo B, Traore L, Mohamed A, Diallo M. [Migrant foreign body of the oesophagus: report of a case]. Rev Laryngol Otol Rhinol (Bord) 2013; 134:169-171. [PMID: 24974413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVE Evaluate the risk brought by the traditional practice in the evolution of the foreign bodies of the aesophagus. CASE REPORT 30 years old male with migration from the oesophagus of a fish bone in soft tissue of the neck, which could have been favored by the traditional practice. The diagnosis of migration was suspected when a laterocervical mass appeared after a traditional processing. The rigid aesophagoscopy was negative and the scanner allowed to identify the foreign body in an extraluminal location. It was removed by cervicotomy. Postoperative was uneventful.
Collapse
|
29
|
Timbo SK, Keita MA, Doumbia-Singare K, Togola-Konipo F, Traore L, Guindo B, Soumaoro S, Ag Mohamed A. [Medical handicap and otorhinolaryngologic foreign bodies about 4 original cases]. Mali Med 2010; 25:50-55. [PMID: 21435999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The multiple variant of aero-digestive foreign bodies' pathology determine many complex aspects with regard to their physiopathology, nature, and their location. The presence of a medical handicap or any particular condition could increase morbidity and expose to major risks. We are reporting here about 4 cases including an esophagus foreign body in a leprosies patient, an esophago-gastric case in a mental disorder patient, and two laryngeal-tracheal-bronchial cases during epileptic episodes. From the rarity of such accidents in an adult to their happening during a loss of consciousness or a delirious state, the clinical history is always missing. The symptoms are atypical and may misguide. The classical penetration syndrome cannot be reported. Only a clinical examination carefully conducted and completed with targeted para clinical examinations can help make early diagnosis. Endoscopy of the Esophagus on one hand, and endoscopy of the trachea and lungs on the other hand were used to extract these foreign bodies.
Collapse
Affiliation(s)
- S K Timbo
- Service ORL CHU Gabriel Touré - BP 267 Bamako Mali.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Traore L. 177 Résultats anatomique et fonctionnel des cataractes traumatiques chez les sujets de plus de 15 ans à l’IOTA. J Fr Ophtalmol 2009. [DOI: 10.1016/s0181-5512(09)73305-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Schémann JF, Guinot C, Traore L, Zefack G, Dembele M, Diallo I, Traore A, Vinard P, Malvy D. Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali. Acta Trop 2007; 101:40-53. [PMID: 17239332 DOI: 10.1016/j.actatropica.2006.12.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2006] [Revised: 11/09/2006] [Accepted: 12/07/2006] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Trachoma, caused by repeated ocular infections with Chlamydia trachomatis is an important cause of blindness. Mass azithromycin distribution is part of current recommended strategies for controlling trachoma. In order to ascertain an efficient strategy model at an acceptable cost, an intervention study was conducted in Mali between May 2000 and February 2002. METHODS Three azithromycin administration strategies were evaluated: mass community-based treatment of all residents (strategy I), treatment of all children under 11 years of age and of women between 15 and 50 (strategy II), and treatment targeted to inhabitants of households where at least one child had clinically active trachoma diagnosed (strategy III). In a particular Malian area in which trachoma was known to be mesoendemic, three villages were selected for each of the three strategies. According to the strategy allocation, adults were eventually given a single dose of 1g azithromycin, and children a unique dose of 20 mg/kg. Moreover, cleanliness and washing of children's faces were assessed, and additional questions were addressed about education, environmental and socio-economic conditions for each household at baseline. Ophthalmic examination was performed at baseline and 1, 6 and 12 months after inclusion. The outcome variable was clinically active trachoma frequency 12 months after intervention among children under 11 years of age. A descriptive analysis was performed, and then logistic regression models were built to test the efficiency of the three strategies. RESULTS Among children under 11 years of age, the active trachoma prevalence fell dramatically in each strategy, from 23.7% to 6.4% in strategy I, from 20.8% to 6.8% in strategy II, and from 20.2% to 8.5% in strategy III. After adjustment on age (adjusted odds ratio [AOR] = 0.81; 95% confidence interval [95% CI]: 0.75-0.87) and on active trachoma occurrence at baseline (AOR = 3.81; [95% CI]: 2.70-5.39), the multiple logistic regression model showed that both strategies I and II gave similar results, while strategy III appeared significantly less effective (AOR = 1.56; [95% CI]: 1.00-2.43). CONCLUSION In mesoendemic trachoma areas, targeted treatment to all children under 11 years of age and women between 15 and 50 (strategy II) was as effective as indiscriminate mass distribution (strategy I) and more effective than treatment targeted to inhabitants of households where at least one child had active trachoma diagnosed (strategy III). Strategy II could therefore reduce the prevalence and intensity of trachoma infection at a lower cost than mass community-based treatment of all residents (strategy I).
Collapse
Affiliation(s)
- J-F Schémann
- Institute of Research for Development (IRD), UR024, Centre IRD de Hann BP 1386, Dakar, Senegal.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Traore J, Boitte J, Bogoreh I, Traore L, Diallo A. 110 Drépanocytose et atteintes rétiniennes : étude prospective de 38 cas à l’Institut d’Ophtalmologie Tropicale de l’Afrique de Bamako. J Fr Ophtalmol 2005. [DOI: 10.1016/s0181-5512(05)74506-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Schémann JF, Banou A, Malvy D, Guindo A, Traore L, Momo G. National immunisation days and vitamin A distribution in Mali: has the vitamin A status of pre-school children improved? Public Health Nutr 2003; 6:233-44. [PMID: 12740072 DOI: 10.1079/phn2002432] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVES The impact on vitamin A status of the distribution of vitamin A during national immunisation days (NIDs) has not been well established despite strong promotion by international agencies and donors. Using a pre-post design, the change in prevalence of vitamin A deficiency was examined in pre-school children in Mali. DESIGN Two cross-sectional surveys were conducted in Mopti region, the first in March 1997 before this strategy was adopted and the second in March 1999, four-and-a-half months after a mass distribution of vitamin A during NIDs. SUBJECTS AND SETTING We compared the vitamin A status of children aged 12 to 66 months targeted in 1999 by NIDs with the status of children in the same age group in 1997. Infectious events of the previous two weeks were concurrently recorded. Within the 1999 sample, the status of recipient and non-recipient children was also compared. RESULTS In 1997, the prevalence of xerophthalmia (defined by the presence of night blindness and/or Bitot spots) was 6.9% (95% confidence interval (CI) 5.1-9.2) and the modified retinol dose response (MRDR) test proved abnormal in 77.8% of 12-66-month-old children (95% CI 68.27-85.17). In 1999 this picture had improved significantly, both for xerophthalmia prevalence, 3.3% (95% CI 2.1-5.2), and abnormal MRDR test response, 63.1% (95% CI 54.25-71.23). The infectious morbidity rates between 1997 and 1999 tended to decrease. No significant improvement was found among children older than those targeted by NIDs. In 1999, children who received vitamin A had a lower risk for xerophthalmia (3.0% for recipients vs. 8.7% for non-recipients) and experienced fewer infectious events. CONCLUSIONS The clinical and biological vitamin A status of pre-school children improved between 1997 and 1999. Mass distribution of vitamin A appears to reduce the occurrence of xerophthalmia and would seem to be associated with a decrease in other related illnesses. Vitamin A supplementation during NIDs should be given a high priority when vitamin A deficiency remains a public health problem.
Collapse
Affiliation(s)
- J F Schémann
- Institute of African Tropical Ophthalmology (IOTA), BP 248 Bamako, Mali.
| | | | | | | | | | | |
Collapse
|
34
|
Timbo SK, Konipo-Togola F, Mohamed AA, Keita MA, Sacko HB, Traore L. [Laryngeal papillomatosis in Mali. Apropos of 19 cases collected at the Gabriel Touré Hospital of Bamako]. Bull Soc Pathol Exot 2002; 95:31-3. [PMID: 12012961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
From 1994 to 1999, 19 cases of laryngeal papillomatosis were observed. The sex-ratio M/F was 0.9 and the mean age 10 years. The motive for consulting was dyspnoea for 45% of the cases and in all these cases resulted in emergency tracheotomy. The only available means of intervention was peeling under general anaesthesia. An anatomopathological examination could be carried out for only 63.1% of cases. Prevalence of the disease has been under-estimated for reasons of late diagnosis and the inaccessibility to health structures for some cases.
Collapse
Affiliation(s)
- S K Timbo
- Service ORL, Hôpital Gabriel Touré, BP 267, Bamako, Mali
| | | | | | | | | | | |
Collapse
|
35
|
Abstract
OBJECTIVES Prior to commencing a campaign to eliminate blinding trachoma in Mali, a national disease prevalence survey was conducted from March 1996 to June 1997. The prevalence of trachoma was estimated and potential risk factors were studied. METHODS In each of Mali's seven regions (excluding the capital Bamako), a sample of 30 clusters was taken from the general population, in accordance with the principle of probability proportional to the size of the community. All children under 10 years of age were examined. The simplified clinical coding system proposed by the World Health Organization was used. The position of each village was established and subsequently related to the nearest meteorological station. Socioeconomic and environmental information was collected at both village and household level. The mother or caretaker of each child was questioned about availability and use of water for washing the child. At the time of examination, facial cleanliness and the presence of flies on the face were noted. RESULTS A total of 15,187 children under 10 years of age were examined. The prevalence of active trachoma (follicular [TF] or intense trachoma [TI]) was 34.9% (95% CI : 32.3-37.6) and the prevalence of TI was 4.2% (95% CI : 3.5-5.0). Aridity/environmental dryness appears to be a risk factor influencing the current geographical distribution of trachoma. Small villages had considerably higher trachoma prevalence than their larger neighbours. The proximity of a medical centre and the existence of social organizations such as a women's association were associated with lower levels of trachoma. Crowded living conditions increased the risk. Using a monetary marker of wealth, we observed a linear inverse relation between wealth and trachoma prevalence. The presence of a dirty face was strongly associated with trachoma (odds ratio [OR] = 3.67) as was the presence of flies on the child's face (OR = 3.62). Trachoma prevalence increased with distance to a water source. Disease prevalence decreased with a higher frequency of both face washing and bathing. CONCLUSIONS Of all the risk factors examined, facial cleanliness had the strongest association with the prevalence of trachoma. This was followed by the presence of flies on the child's face. Both face washing and bathing showed beneficial effects. Socioeconomic factors such as wealth were significantly explanatory. It is likely that hygiene education and fly control by environmental improvement could have a very significant impact on the prevalence of trachoma in Mali.
Collapse
Affiliation(s)
- J-F Schémann
- Institute of African Tropical Ophthalmology, BP 248, Bamako, Mali.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
Both vitamin A deficiency and trachoma are important causes of preventable ocular diseases. We examined 10 559 children in Mali for clinical signs of trachoma and of xerophthalmia. In five regions, the mean prevalence of trachoma was 39.3% (95% CI: 37.4-41.2). Clinical xerophthalmia was present among 1.89% of children (1.59-2.25). The diagnosis of xerophthalmia appeared to be associated with active trachoma (OR=2.04 [1.52-2.74]). This association remained after controlling for socio-economic status.
Collapse
|
37
|
Raguenes O, Mercier B, Escoffre M, Traore L, Blouch MT, Robinet A, Abgrall JF, Ferec C. [1691 G to A mutation of the factor V gene: no association with thrombosis of the central retinal vein]. Presse Med 1996; 25:460. [PMID: 8685200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
|
38
|
Traore L, Roux P, Poirot JL, Chouaid C, el Helali N, Marteau-Miltgen M, Denis M, Balmy-Rapontchombo F. Value of an immunofluorescence assay for the detection of Pneumocystis carinii in Bronchoalveolar lavage. J Protozool 1991; 38:198S. [PMID: 1818165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
An indirect immunofluorescence monoclonal antibody assay was found to have higher sensitivity than usual stains for the detection of Pneumocystis carinii, particularly in bronchoalveolar lavage fluids in which there are only a few parasites, as in HIV-patients or in HIV+ patients with prophylaxis or treatment. For patients without any therapy, when different stains give conflicting results, decisions on therapeutic approaches to be used should consider the patient's clinical and biological status. Prospective studies are necessary to evaluate the predictive value of low parasitism in asymptomatic immunosuppressed patients.
Collapse
Affiliation(s)
- L Traore
- Saint-Antoine Hospital, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|